Breast Cancers With Magee Equation Score of Less Than 18, or 18-25 and Mitosis Score of 1, Do Not Require Oncotype DX Testing: A Value Study

被引:24
作者
Bhargava, Rohit [1 ]
Clark, Beth Z. [1 ]
Dabbs, David J. [1 ]
机构
[1] Univ Pittsburgh, Med Ctr, Dept Pathol, Magee Womens Hosp, Pittsburgh, PA 15260 USA
关键词
Magee equations; Oncotype DX; Breast cancer; Chemotherapy; RECURRENCE SCORE; PROGESTERONE-RECEPTOR; PREDICT; BENEFIT; ASSAY; CHEMOTHERAPY; CARCINOMA; RISK;
D O I
10.1093/ajcp/aqy148
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Objectives To investigate use of Magee equations (MEs) to determine which breast cancer cases can be excluded from Oncotype DX testing. Methods A prospective value study was carried out using data from pathology reports. Results If all three MEs scores were less than 18 or 31 or higher, the cases were labeled do not send for testing. If any or all scores were 18 to 25, cases were labeled do not send if mitosis score was 1. Of the total 205 cases, 146 (71%) were labeled do not send; of these, the correct call was made in 143 (98%) cases. Two of the three discordant cases had associated nontumor factors, likely resulting in higher scores. Conclusions Cases with ME scores less than 18, or 18 to 25 and mitosis score 1, do not require Oncotype DX testing, an estimated saving of US$280,000 per 100 clinical requests.
引用
收藏
页码:316 / 323
页数:8
相关论文
共 29 条
[1]   A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomas [J].
Acs, Geza ;
Esposito, Nicole N. ;
Kiluk, John ;
Loftus, Loretta ;
Laronga, Christine .
MODERN PATHOLOGY, 2012, 25 (04) :556-566
[2]   Routine pathologic parameters can predict Oncotype DXTM recurrence scores in subsets of ER positive patients: who does not always need testing? [J].
Allison, K. H. ;
Kandalaft, P. L. ;
Sitlani, C. M. ;
Dintzis, S. M. ;
Gown, A. M. .
BREAST CANCER RESEARCH AND TREATMENT, 2012, 131 (02) :413-424
[3]  
Auerbach J, 2010, ARCH PATHOL LAB MED, V134, P1697, DOI 10.1043/2009-0439-OAR.1
[4]  
Chaudhary Lubna N, 2016, Hematol Oncol Stem Cell Ther, V9, P48, DOI 10.1016/j.hemonc.2015.12.001
[5]   Adjust cut-off values of immunohistochemistry models to predict risk of distant recurrence in invasive breast carcinoma patients [J].
Chen, Yen-Ying ;
Tseng, Ling-Ming ;
Yang, Ching-Fen ;
Lien, Pei-Ju ;
Hsu, Chih-Yi .
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2016, 79 (12) :649-655
[6]  
Clark BZ, 2013, APPL IMMUNOHISTO M M, V21, P287, DOI 10.1097/PAI.0b013e31826f80c9
[7]  
Dabbs DJ, J CLIN ONCOL
[8]   Estimating the OncotypeDX score: validation of an inexpensive estimation tool [J].
Eaton, Anne A. ;
Pesce, Catherine E. ;
Murphy, James O. ;
Stempel, Michelle M. ;
Patil, Sujata M. ;
Brogi, Edi ;
Hudis, Clifford A. ;
El-Tamer, Mahmoud .
BREAST CANCER RESEARCH AND TREATMENT, 2017, 161 (03) :435-441
[9]   Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors [J].
Farrugia, Daniel J. ;
Landmann, Alessandra ;
Zhu, Li ;
Diego, Emilia J. ;
Johnson, Ronald R. ;
Bonaventura, Marguerite ;
Soran, Atilla ;
Dabbs, David J. ;
Clark, Beth Z. ;
Puhalla, Shannon L. ;
Jankowitz, Rachel C. ;
Brufsky, Adam M. ;
Lembersky, Barry C. ;
Ahrendt, Gretchen M. ;
McAuliffe, Priscilla F. ;
Bhargava, Rohit .
MODERN PATHOLOGY, 2017, 30 (08) :1078-1085
[10]   Histopathologic variables predict Oncotype DX™ Recurrence Score [J].
Flanagan, Melina B. ;
Dabbs, David J. ;
Brufsky, Adam M. ;
Beriwal, Sushil ;
Bhargava, Rohit .
MODERN PATHOLOGY, 2008, 21 (10) :1255-1261